



**CONTACT:** Trish Cetrone, 925-787-4283 [tcetrone@chasepr.com](mailto:tcetrone@chasepr.com)  
Julie Chase, 415-710-7108, [jchase@chasepr.com](mailto:jchase@chasepr.com)  
Chase Communications

**SANTEN ANNOUNCES VISTAKON PHARMACEUTICALS TO LAUNCH  
IQUIX<sup>®</sup> IN THE U.S.**

Newer-Generation Fluoroquinolone Is Santen's Fourth FDA-Approved Drug

**NAPA, Calif. (October 29, 2007)** -- Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd., Osaka, Japan, announced the launch of its fourth product IQUIX<sup>®</sup> (levofloxacin ophthalmic solution) 1.5%, through an agreement with Vistakon Pharmaceuticals, LLC. The agreement gives Vistakon Pharmaceuticals exclusive U.S. marketing and distribution rights for IQUIX, Santen's most recent ocular anti-infective medication. IQUIX is the only newer-generation fluoroquinolone approved by the U.S. Food and Drug Administration for the treatment of corneal ulcers.

In 2003, Santen granted Vistakon Pharmaceuticals sole U.S. distribution rights for its other three products: QUIXIN<sup>®</sup> (levofloxacin ophthalmic solution) 0.5%, BETIMOL<sup>®</sup> (timolol ophthalmic solution) 0.25%, 0.5% and ALAMAST<sup>®</sup> (pemirolast potassium ophthalmic solution) 0.1%. Santen continues its responsibility for manufacturing, clinical and regulatory activities associated with all four of the products.

"Santen has world-class R&D and clinical development capabilities," says Santen Inc.'s President and CEO Adrienne Graves, PhD. "IQUIX is an innovative new product and we are confident that Vistakon Pharmaceuticals will leverage its experience with QUIXIN to increase our penetration in the anti-infective market."

In the U.S., Santen has recently expanded its clinical and business development efforts to further support global expansion. Currently, Santen is focused on the development of two main products\*:

- DE-101 (generic name: Rivoglitazone), currently in Phase II clinical trials, is expected to show a potent effect on corneal and conjunctival epithelial disorders by directly acting on the corneal and conjunctival epithelial cells. It has an innovative mechanism of action which differs from any other existing treatment or drug candidate in development. The compound is currently under development by Daiichi Sankyo as an oral anti-diabetic in the USA.
- DE-104 (ROCK inhibitor), currently in Phase I clinical trials, is a glaucoma compound under co-development with Ube Industries for treatment of glaucoma and ocular hypertension. This compound, which has a unique mechanism of action from other existing drugs, is expected to show a strong IOP-reduction by promoting aqueous humor outflow by acting directly on trabecular cells

“Santen is pursuing global expansion of its pharmaceutical business and the U.S. market is an important element in that strategy,” says Schalon Newton, EDM, Santen’s Vice President of Strategic Marketing & Business Development. “We are committed to expanding our current pipeline and identifying the next generation of compounds to develop and market. We also are actively pursuing new, externally sourced compounds.”

Santen Inc., based in Napa, California, is the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., an \$850 million global company headquartered in Osaka, Japan since 1890. Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide. Santen has subsidiaries in the U.S., Europe and Asia, including its wholly-owned Napa, California-based Santen Inc. For more information, visit [www.santeninc.com](http://www.santeninc.com).

###

ALAMAST and BETIMOL are registered trademarks of Santen Pharmaceutical, Co., Ltd., Osaka, Japan. IQUIX and QUIXIN are licensed trademarks of Daiichi-Sankyo Co., Ltd., Tokyo, Japan, manufactured by Santen Oy, Tampere, Finland, and marketed by VISTAKON® Pharmaceuticals, LLC. VISTAKON® is a registered trademark of VISTAKON® Pharmaceuticals, LLC, Jacksonville, Florida

\* Editor’s Note: Santen’s global product pipeline includes many more prescription pharmaceuticals in varying clinical trial phases. A detailed listing is available in the company’s 2007 Annual Report and can be accessed at [www.santeninc.com](http://www.santeninc.com).